Olema Pharmaceuticals focuses on next-generation endocrine therapies for ER+/HER2- metastatic breast cancer, led by palazestrant, a novel CERAN/SERD oral agent progressing through pivotal Phase 3 trials both as monotherapy and combined with ribociclib under a Novartis collaboration. The company has reported widening losses consistent with clinical-stage operations but maintains robust liquidity exceeding $48 million in cash and approximately $515 million in current assets to fund ongoing development and potential commercialization. Key readouts are expected in late 2026 and 2028, setting the stage for NDA filings and possible FDA approvals. Olema faces typical biotech risks around trial outcomes and commercial infrastructure build decisions while leveraging partnerships to navigate competitive oncology markets.